DHR vs JNJ: Which Is the Better Buy?
Side-by-side comparison of Danaher Corporation and Johnson & Johnson — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-06-20.
Danaher Corporation · Healthcare
$177.17
+8.9% upside to fair value
Grade B
High Quality
VS
Johnson & Johnson · Healthcare
$228.39
-20.6% upside to fair value
Grade D
High Quality
QuantHub Verdict
DHR has more upside to fair value
(+8.9%).
JNJ trades at a lower forward P/E
(26.3x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
DHR |
JNJ |
| Current Price |
$177.17 |
$228.39 |
| Fair Value Estimate |
$192.90 |
$181.44 |
| Upside to Fair Value |
+8.9%
|
-20.6%
|
| Market Cap |
$125.4B |
$549.8B |
| Forward P/E |
34.1x
|
26.3x
|
| EV / EBITDA |
20.8x
|
17.4x
|
| Price / Sales |
5.1x
|
5.7x
|
| Price / FCF |
23.7x
|
30.9x
|
| Revenue Growth YoY |
+3.7%
|
+9.9%
|
| Gross Margin |
60.7%
|
69.1%
|
| Operating Margin |
21.0%
|
26.9%
|
| Return on Equity |
7.1%
|
26.3%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
4.22%
|
3.24%
|
| Analyst Consensus |
Strong Buy
|
Buy
|
Investment Thesis
Danaher Corporation operates in the healthcare sector, specializing in medical diagnostics and research tools through three balanced platforms: Biotechnology, Life Sciences, and Diagnostics. The company benefits from a durable competitive moat supported by the Danaher Business System, disciplined capital allocation, and a platform-centric organizational structure. Despite modest revenue growth of…
Johnson & Johnson is a leading global healthcare company focused on innovative medicine and MedTech following the Kenvue consumer spin-off. It benefits from a durable competitive moat with strong market positions in pharmaceuticals and medical devices, supported by a long-tenured management team and disciplined capital allocation. However, the stock is currently very expensive, trading approximat…
Accumulation Zones
| Metric |
DHR |
JNJ |
| Zone Low |
$144.68 |
$136.08 |
| Zone High |
$163.97 |
$154.22 |
| In Buy Zone? |
No
|
No
|